10/18/2024

Janusmed sex and gender

Janusmed sex and gender – misoprostol

Janusmed Sex and Gender is a knowledge database providing information on sex and gender aspects of drug treatment. The knowledge database is primarily intended to be used by physicians and healthcare professionals. The texts are general and should not be considered as treatment guidelines. The individual patient’s physician is responsible for the patient’s drug treatment.

Back to index
B B
B B

Misoprostol

Misoprostol

Class : B

Show all info

Print

Contact us

  1. Cytotec (misoprostol). Summary of Product Characteristics. Medical Products Agency (MPA); 2012.

  2. Physicians' Digital Reference. http://www.pdr.net. [cited 2017-07-12].

  3. CYTOTEC (misoprostol). Summary of Product Characteristics. http://www.medicines.org.uk/emc [cited 2017-07-12]

  4. Leontiadis GI, Sreedharan A, Dorward S, Barton P, Delaney B, Howden CW et al. Systematic reviews of the clinical effectiveness and cost-effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding. Health Technol Assess. 2007;11:iii-iv, 1-164.

  5. Hawkey CJ, Wilson I, Naesdal J, Långström G, Swannell AJ, Yeomans ND. Influence of sex and Helicobacter pylori on development and healing of gastroduodenal lesions in non-steroidal anti-inflammatory drug users. Gut. 2002;51:344-50.

  6. Hawkey CJ, Karrasch JA, Szczepañski L, Walker DG, Barkun A, Swannell AJ et al. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group. N Engl J Med. 1998;338:727-34.

  7. Misoprostol (misoprostol) DailyMed. DailyMed [www]. US National Library of Medicine. [updated 2016-02-12, cited 2017-07-12].

  8. Waiser J, Böhler T, Stoll J, Schumann B, Budde K, Neumayer HH. The immunosuppressive potential of misoprostol--efficacy and variability. Clin Immunol. 2003;109:288-94.

  9. Bergmann JF, Pichot L, de Pouvourville G, Chassany O, Caulin C, Segrestaa JM. [Prevention of gastroduodenal lesions induced by non-steroidal anti-inflammatory agents Economic analysis from a survey of 356 physicians]. Presse Med. 1992;21:979-82.

  10. Clinard F, Bardou M, Sgro C, Lefevre N, Raphael F, Paille F et al. Non-steroidal anti-inflammatory and cytoprotective drug co-prescription in general practice A general practitioner-based survey in France. Eur J Clin Pharmacol. 2001;57:737-43.

  11. Silverstein FE, Graham DY, Senior JR, Davies HW, Struthers BJ, Bittman RM et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1995;123:241-9.

  1. Cytotec (misoprostol). Summary of Product Characteristics. Medical Products Agency (MPA); 2012.
  2. Physicians' Digital Reference. http://www.pdr.net. [cited 2017-07-12].
  3. CYTOTEC (misoprostol). Summary of Product Characteristics. http://www.medicines.org.uk/emc [cited 2017-07-12]
  4. Leontiadis GI, Sreedharan A, Dorward S, Barton P, Delaney B, Howden CW et al. Systematic reviews of the clinical effectiveness and cost-effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding. Health Technol Assess. 2007;11:iii-iv, 1-164.
  5. Hawkey CJ, Wilson I, Naesdal J, Långström G, Swannell AJ, Yeomans ND. Influence of sex and Helicobacter pylori on development and healing of gastroduodenal lesions in non-steroidal anti-inflammatory drug users. Gut. 2002;51:344-50.
  6. Hawkey CJ, Karrasch JA, Szczepañski L, Walker DG, Barkun A, Swannell AJ et al. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group. N Engl J Med. 1998;338:727-34.
  7. Misoprostol (misoprostol) DailyMed. DailyMed [www]. US National Library of Medicine. [updated 2016-02-12, cited 2017-07-12].
  8. Waiser J, Böhler T, Stoll J, Schumann B, Budde K, Neumayer HH. The immunosuppressive potential of misoprostol--efficacy and variability. Clin Immunol. 2003;109:288-94.
  9. Bergmann JF, Pichot L, de Pouvourville G, Chassany O, Caulin C, Segrestaa JM. [Prevention of gastroduodenal lesions induced by non-steroidal anti-inflammatory agents Economic analysis from a survey of 356 physicians]. Presse Med. 1992;21:979-82.
  10. Clinard F, Bardou M, Sgro C, Lefevre N, Raphael F, Paille F et al. Non-steroidal anti-inflammatory and cytoprotective drug co-prescription in general practice A general practitioner-based survey in France. Eur J Clin Pharmacol. 2001;57:737-43.
  11. Silverstein FE, Graham DY, Senior JR, Davies HW, Struthers BJ, Bittman RM et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1995;123:241-9.